| Literature DB >> 31121991 |
Damien Mooney1,2,3, Catherine Coxon4,5, Karl G Richards6,7, Laurence Gill8,9, Per-Erik Mellander10, Martin Danaher11.
Abstract
A comprehensive multiresidue method was developed and validated for the determination of 40 anthelmintic compounds, including 13 transformation products, in surface and groundwater samples at sub nanogram per litre (ng L-1) levels. Anthelmintic residues were extracted from unfiltered water samples using polymeric divinylbenzene solid phase extraction (SPE) cartridges, and eluted with methanol: acetone (50:50, v/v). Purified extracts were concentrated, filtered and injected for UHPLC-MS/MS determination. The method recovery (at a concentration representative of realistic expected environmental water levels based on literature review) ranged from 83-113%. The method was validated, at three concentration levels, in accordance to Commission Decision 2002/657/EC and SANTE/11813/2017 guidelines. Trueness and precision, under within-laboratory reproducibility conditions, ranged from 88-114% and 1.1-19.4%, respectively. The applicability of the method was assessed in a pilot study whereby 72 different surface and groundwater samples were collected and analysed for the determination of these 40 compounds for the first time in Ireland. This is the most comprehensive method available for the investigation of the occurrence of both anthelmintic parent compounds and their transformation products in raw, unfiltered environmental waters.Entities:
Keywords: UHPLC-MS/MS; anthelmintics; emerging organic contaminants; environmental water; solid phase extraction; transformation products; veterinary drugs
Mesh:
Substances:
Year: 2019 PMID: 31121991 PMCID: PMC6572551 DOI: 10.3390/molecules24101978
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Validation criteria adhered to, with corresponding legislative guideline.
| Parameter | Performance Criteria | Guideline a |
|---|---|---|
|
| ||
| Points | Minimum 3 | 2002/657 |
| Relative retention (RRT) | ≤2.5% | 2002/657 |
| Ion ratio tolerance (ΔR) | 20–50% | 2002/657 |
|
| Interferences: ≤10% lowest calibrant | 2002/657 |
|
| Regression coefficient R2 ≥ 0.98 | 2002/657 |
|
| 70–120% | SANTE |
|
| ≤20% | SANTE |
|
| 70–120% | SANTE |
a 2002/657 = European Commission Decision 2002/657/EC [37], SANTE = SANTE/11813/2017 [38].
Figure 1Mean recoveries (%) and precision (%RSD, shown by error bars)(n = 3) for assessment of: (a) four different SPE Cartridges (Bond Elut ENV, Bond Elut Plexa, Oasis HLB and UCT HL-DVB) eluted with 50: 50 MeOH: MeCN (v/v) (10 mL) (b) seven different eluent compositions: (A) = 50/50 MeOH/MeCN (10 mL), (B) = 50/50 MeOH/MeCN (5 mL) + Acetone (5 mL), (C) = 50/50 MeOH/MeCN (5 mL) + MTBE (5 mL) (D) = 50/50 MeOH/Acetone (10 mL), (E) = 50/50 MeCN/MTBE (10 mL), (F) = 100% Acetone (10 mL) and (G) = 100% MTBE (10 mL) using the HL-DVB cartridge (200 mg, 6 mL) and (c) three different volumes (0, 15 and 25 mL) of water: methanol (90:10, v/v) wash solution using the same HL-DVB cartridge.
Calibration range, mean linearity (of n = 5 runs), and results of matrix effects (ME) (n = 30) for each of the 40 anthelmintic compounds.
| Analyte | Abbreviation | P/TP | Labelled IS Used | Calibration Range (ng L−1) | Linearity R2 | Mean ME (%) ( | ME RANGE (%) | RSD No IS ( | RSD with IS ( | |
|---|---|---|---|---|---|---|---|---|---|---|
| Min | Max | |||||||||
|
| ||||||||||
| Albendazole | ABZ | P | ABZ-d3 | 1–1000 | 0.997 | 27.1 | 8.2 | 47.3 | 9.3 | 3.0 |
| Albendazole sulphoxide | ABZ-SO | TP | ABZ-SO-d3 | 1–1000 | 0.994 | 93.4 | 13.8 | 212 | 31.6 | 7.1 |
| Albendazole sulphone | ABZ-SO2 | TP | ABZ-SO2-d3 | 1–1000 | 0.996 | 60.8 | 29 | 120 | 18.2 | 6.5 |
| Albendazole-amino-sulphone | ABZ-NH2-SO2 | TP | ABZ-NH2-SO2-d3 | 0.5–1000 | 0.998 | 16.9 | −1.4 | 28.0 | 6.9 | 4.0 |
| Cambendazole | CAM | P | FBZ-d3 | 0.5–1000 | 0.997 | 9.7 | −5.1 | 24.2 | 6.6 | 7.2 |
| Fenbendazole | FBZ | P | FBZ-d3 | 0.5–1000 | 0.995 | 23.1 | 1.0 | 44.9 | 9.3 | 2.3 |
| Oxfendazole | OXF | TP | FBZ-SO-d3 | 1–1000 | 0.993 | 42.0 | 11.6 | 106.2 | 18.5 | 6.4 |
| Fenbendazole sulphone | FBZ-SO2 | TP | FBZ-SO2-d3 | 1–1000 | 0.998 | 47.5 | 8.1 | 165.7 | 25.5 | 3.3 |
| Flubendazole | FLU | P | FLU-d3 | 1–1000 | 0.996 | 33.3 | 7.4 | 108.2 | 14.1 | 3.7 |
| Amino-flubendazole | FLU-NH2 | TP | TCB-NH2 (pos) | 1–1000 | 0.995 | 11.5 | −3.7 | 29.8 | 8.0 | 8.8 |
| Hydroxy-flubendazole | FLU-OH | TP | MBZ-OH-d3 | 1–1000 | 0.997 | 3.7 | −12.9 | 27.4 | 12.1 | 7.6 |
| Mebendazole | MBZ | P | MBZ-d3 | 1–1000 | 0.994 | 45.0 | 11.4 | 104.2 | 18.1 | 3.6 |
| Amino-mebendazole | MBZ-NH2 | TP | TCB-NH2 (pos) | 1–1000 | 0.995 | 15.1 | 0 | 36.3 | 7.2 | 8.5 |
| Hydroxy-mebendazole | MBZ-OH | TP | MBZ-OH-d3 | 1–1000 | 0.998 | 27.4 | 3.8 | 64.2 | 13.1 | 4.6 |
| Oxibendazole | OXI | P | OXI-d7 | 0.5–1000 | 0.994 | 9.3 | −2.5 | 21.6 | 5.8 | 4.5 |
| Triclabendazole | TCB | P | TCB-d3 | 0.5–1000 | 0.997 | 3.6 | −14.2 | 27.4 | 8.0 | 3.3 |
| Triclabendazole-sulphoxide | TCB-SO | TP | TCB-NH2(neg) | 4–20 | 0.967 | −3.0 | −45.0 | 47.8 | 25.2 | 24.7 |
| Triclabendazole-sulphone | TCB-SO2 | TP | TCB-NH2(neg) | 4–20 | 0.891 | 5.2 | −25.4 | 57.8 | 18.2 | 19.8 |
| Thiabendazole | TBZ | P | TBZ-13C6 | 0.5–1000 | 0.999 | 9.1 | −6.8 | 26.6 | 6.7 | 2.7 |
| 5-Hydroxy-Thiabendazole | TBZ-OH | TP | ABZ-NH2-SO2-d3 | 0.5–200 | 0.991 | −6.4 | −23.8 | 12.7 | 9.6 | 7.2 |
|
| ||||||||||
| Abamectin | ABA | P | SEL | 10–2000 | 0.996 | 20.4 | −4.1 | 45.7 | 9.7 | 7.5 |
| Doramectin | DORA | P | SEL | 10–1000 | 0.993 | 77.8 | 13.8 | 130.9 | 16.0 | 15.2 |
| Emamectin | EMA | P | SEL | 0.5–200 | 0.996 | 24.8 | 3.4 | 37.8 | 7.7 | 8.2 |
| Eprinomectin | EPRINO | P | SEL | 20–2000 | 0.997 | 6.8 | −17.9 | 25.7 | 9.9 | 8.3 |
| Ivermectin | IVER | P | SEL | 10–2000 | 0.996 | 5.2 | −22.5 | 27.2 | 9.6 | 7.9 |
| Moxidectin | MOXI | P | SEL | 10–2000 | 0.996 | 34.9 | −9.1 | 76.3 | 16.3 | 13.7 |
|
| ||||||||||
| Bithionol | BITH | P | RAFOX-13C6 | 5–1000 | 0.995 | 32.0 | −1.4 | 50 | 10.6 | 5.4 |
| Closantel | CLOS | P | CLOS-13C6 | 2–1000 | 0.997 | −3.9 | −12.1 | 5.2 | 5.4 | 2.8 |
| Niclosamide | NICLOS | P | SAL | 1–200 | 0.991 | 13.0 | −5 | 33.3 | 8.3 | 5.1 |
| Nitroxynil | NITROX | P | NITROX-13C6 | 10–1000 | 0.993 | 28.6 | −5.7 | 73.2 | 14.9 | 14.2 |
| Oxyclozanide | OXY | P | OXY-13C6 | 5–1000 | 0.996 | 42.8 | 18.2 | 70.9 | 9.5 | 10.4 |
| Rafoxanide | RAFOX | P | RAFOX-13C6 | 2–1000 | 0.994 | 23.0 | 2 | 41.2 | 10.5 | 3.4 |
|
| ||||||||||
| Morantel | MOR | P | TBZ-13C6 | 1–1000 | 0.997 | 13.3 | −2.5 | 34.1 | 7.4 | 1.6 |
|
| ||||||||||
| Levamisole | LEV | P | LEVA-d5 | 0.5–1000 | 0.999 | 12.4 | −2.5 | 33.7 | 7.4 | 2.0 |
|
| ||||||||||
| Coumaphos | COUMA | P | ABZ-d3 | 5–200 | 0.986 | 47.0 | 10.1 | 87.7 | 12.9 | 8.4 |
| Coumaphos-Oxon | COUMA-O | P | FBZ-d3 | 1–1000 | 0.992 | 16.2 | 3.9 | 31.9 | 6.0 | 7.6 |
| Haloxon | HALOX | P | ABZ-d3 | 5–500 | 0.989 | 25.5 | −73.8 | 55 | 12.0 | 7.2 |
|
| ||||||||||
| Monepantel | MONE | P | CLOS-13C6 | 5–400 | 0.991 | 16.7 | −6.1 | 31.8 | 7.2 | 8.5 |
| Monepantel-sulphone | MONE-SO2 | TP | CLOS-13C6 | 1–400 | 0.993 | 14.0 | −4.4 | 28.8 | 7.0 | 7.4 |
|
| ||||||||||
| Clorsulon | CLOR | P | SAL | 40–2000 | 0.991 | −15.1 | −48.8 | 9.2 | 18.7 | 15.6 |
P = Parent compound, TP = Transformation product, IS = Internal standard, R2 = regression coefficient, ME = Matrix effects where positive values indicate ion enhancement, while negative values indicate ion suppression. Matrix effect study was carried out at a concentration of 100 ng L−1 for all analytes except CLOR, BITH and MOR, which were at 200 ng L−1 RSD = relative standard deviation.
Figure 2Overlay of LC-MS/MS chromatograms for the 40 anthelmintic residues in a blank water sample fortified at concentrations equivalent to the limit of quantification (LOQ) (see Table 2) for each analyte.
Validation trueness and precision (RSD) under repeatability conditions (WLr) (n = 6) and reproducibility conditions (WLR) (n = 18) at three concentration levels for 40 anthelmintics with respective method recovery, LOD and LOQ values (ng L−1).
| Analyte | Validated Levels L1, L2, L3 (ng L−1) | WLr Trueness (RSDr) (%) a | WLR Trueness (RSDWR) (%) b | LOD c (ng L−1) | LOQ d (ng L−1) | Recovery % (RSD%, | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| L1 | L2 | L3 | L1 | L2 | L3 | 20/40 ng L−1 | 200/400 ng L−1 | ||||
|
| |||||||||||
| ABZ | 5, 50, 200 | 100 (5.6) | 100 (3.0) | 97 (1.5) | 102 (3.6) | 100 (3.2) | 98 (2.8) | 0.125 | 1.0 | 94 (4.7) | 94 (0.5) |
| ABZ-SO | 5, 50, 200 | 113 (10.8) | 97 (7.3) | 101 (4.7) | 107 (13.5) | 99 (9.9) | 99 (5.2) | 0.2 | 1.0 | 95 (1.3) | 114 (5.5) |
| ABZ-SO2 | 5, 50, 200 | 95 (7.3) | 96 (4.5) | 99 (2.5) | 105 (6.4) | 99 (3.2) | 99 (3.2) | 0.165 | 1.0 | 92 (2.1) | 105 (5.6) |
| ABZ-NH2-SO2 | 5, 50, 200 | 103 (3.1) | 101 (1.4) | 101 (1.1) | 101 (3.7) | 99 (2.3) | 100 (3.9) | 0.165 | 0.5 | 93 (4.0) | 91 (7.6) |
| CAM | 5, 50, 200 | 103 (4.0) | 96 (1.4) | 97 (1.1) | 102 (4.3) | 101 (3.9) | 100 (3.1) | 0.165 | 0.5 | 94 (3.2) | 92 (6.0) |
| FBZ | 5, 50, 200 | 103 (4.5) | 97 (2.0) | 100 (1.3) | 105 (6.7) | 100 (3.8) | 99 (2.3) | 0.1 | 0.5 | 89 (4.6) | 109 (1.9) |
| OXF | 5, 50, 200 | 87 (11.4) | 100 (5.4) | 101 (3.3) | 101 (15.1) | 98 (6.3) | 98 (6.4) | 0.25 | 1.0 | 94 (6.5) | 103 (4.8) |
| FBZ-SO2 | 5, 50, 200 | 99 (2.7) | 96 (1.6) | 97 (0.8) | 101 (5.1) | 99 (3.0) | 99 (1.7) | 0.20 | 1.0 | 97 (3.2) | 102 (5.5) |
| FLU | 5, 50, 200 | 107 (7.2) | 95 (5.5) | 95 (2.1) | 102 (7.1) | 97 (4.3) | 100 (3.3) | 0.1 | 1.0 | 97 (4.9) | 97 (2.5) |
| FLU-NH2 | 5, 50, 200 | 107 (3.6) | 104 (3.4) | 97 (2.4) | 105 (4.8) | 103 (2.9) | 98 (3.4) | 0.05 | 1.0 | 94 (5.1) | 102 (1.8) |
| FLU-OH | 5, 50, 200 | 97 (6.8) | 109 (4.4) | 103 (2.3) | 99 (5.6) | 102 (4.3) | 101 (3.1) | 0.3 | 1.0 | 95 (4.3) | 99 (3.7) |
| MBZ | 5, 50, 200 | 105 (5.3) | 99 (3.6) | 97 (2.0) | 102 (6.1) | 97 (3.9) | 98 (2.6) | 0.125 | 1.0 | 97 (4.0) | 102 (0.9) |
| MBZ-NH2 | 5, 50, 200 | 104 (3.4) | 104 (3.1) | 96 (3.8) | 105 (4.8) | 104 (3.5) | 100 (4.1) | 0.3 | 1.0 | 92 (2.0) | 101 (2.4) |
| MBZ-OH | 5, 50, 200 | 102 (2.6) | 107 (1.0) | 100 (1.0) | 103 (4.3) | 101 (4.2) | 99 (2.5) | 0.2 | 1.0 | 96 (3.6) | 104 (5.2) |
| OXI | 5, 50, 200 | 102 (2.7) | 99 (2.7) | 97 (1.0) | 106 (5.2) | 101 (3.3) | 98 (3.2) | 0.125 | 0.5 | 103 (3.3) | 98 (2.4) |
| TCB | 5, 50, 200 | 96 (6.9) | 105 (4.5) | 102 (3.5) | 100 (7.6) | 102 (3.5) | 100 (3.4) | 0.125 | 0.5 | 91 (2.0) | 100 (4.0) |
| TCB-SO | 6, 14, 20 | - | - | - | - | - | - | 1.0 | 4.0 | 80 (4.8) | 92 (6.6) |
| TCB-SO2 | 6, 14, 20 | - | - | - | - | - | - | 1.0 | 4.0 | 97 (7.5) | 103 (4.8) |
| TBZ | 5, 50, 200 | 102 (3.8) | 99 (1.0) | 98 (0.6) | 103 (3.2) | 99 (2.4) | 100 (2.0) | 0.1 | 0.5 | 99 (3.1) | 98 (3.2) |
| TBZ-OH | 5, 50, 150 | 110 (1.5) | 101 (1.2) | 93 (0.7) | 109 (3.3) | 100 (2.1) | 92 (4.1) | 0.1 | 0.5 | 104 (2.0) | 80 (5.1) |
|
| |||||||||||
| ABA | 40,150,500 | 104 (5.4) | 99 (5.0) | 98 (7.3) | 98 (8.5) | 100 (5.6) | 99 (3.2) | 1.0 | 10.0 | 110 (9.0) | 90 (6.0) |
| DORA | 20, 80, 200 | 103 (4.7) | 97 (5.3) | 103 (4.3) | 98 (7.9) | 97 (7.3) | 99 (4.5) | 0.5 | 10.0 | 105 (6.8) | 87 (1.5) |
| EMA | 5, 50, 150 | 107 (4.5) | 96 (9.6) | 104 (8.7) | 108 (5.6) | 104 (6.5) | 102 (5.5) | 0.05 | 0.5 | 102 (5.0) | 87 (4.5) |
| EPRINO | 40, 150, 500 | 96 (3.4) | 99 (4.9) | 104 (2.6) | 100 (8.9) | 101 (3.1) | 102 (2.4) | 5 | 20.0 | 109 (0.8) | 91 (5.6) |
| IVER | 40, 150, 500 | 104 (4.1) | 100 (2.7) | 107 (5.4) | 98 (7.5) | 100 (2.9) | 103 (4.6) | 2.5 | 10.0 | 113 (10.9) | 72 (8.7) |
| MOXI | 40, 150, 500 | 96 (6.4) | 92 (8.7) | 91 (6.5) | 101 (7.8) | 100 (8.0) | 98 (6.5) | 2.0 | 10.0 | 95 (10.8) | 59 (5.0) |
|
| |||||||||||
| BITH | 20, 80, 200 | 112 (5.6) | 112 (4.7) | 104 (2.7) | 114 (7.2) | 106 (4.8) | 101 (3.8) | 1.0 | 5.0 | 98 (10.8) | 84 (3.7) |
| CLOS | 5, 50, 200 | 105 (4.8) | 104 (2.0) | 101 (1.0) | 105 (7.1) | 101 (3.7) | 99 (3.2) | 0.5 | 2.0 | 103 (3.6) | 76 (3.5) |
| NICLOS | 5, 50, 150 | 107 (10.3) | 106 (3.7) | 96 (2.0) | 114 (9.5) | 105 (7.2) | 96 (6.9) | 0.125 | 1.0 | 94 (7.0) | 100 (5.4) |
| NITROX | 20, 80, 200 | 107 (19.5) | 107 (13.2) | 91 (4.6) | 96 (19.4) | 104 (12.4) | 96 (8.7) | 2.5 | 10.0 | 105 (4.6) | 56 (4.7) |
| OXY | 20, 80, 200 | 113 (6.7) | 108 (7.4) | 101 (2.4) | 109 (9.6) | 103 (8.6) | 101 (4.1) | 1.5 | 5.0 | 93 (7.7) | 104 (5.6) |
| RAFOX | 5, 50, 200 | 105 (8.7) | 101 (3.0) | 99 (1.8) | 102 (10.3) | 102 (4.3) | 101 (2.5) | 0.3 | 2.0 | 97 (5.8) | 86 (4.8) |
|
| |||||||||||
| MOR | 5, 50, 200 | 101 (1.8) | 98 (1.4) | 95 (1.8) | 100 (2.3) | 97 (1.9) | 98 (2.8) | 0.3 | 1.0 | 100 (4.0) | 100 (2.5) |
|
| |||||||||||
| LEV | 5, 50, 200 | 102 (1.5) | 100 (1.4) | 100 (0.7) | 102 (2.1) | 100 (1.1) | 101 (1.7) | 0.125 | 0.5 | 89 (5.7) | 96 (1.9) |
|
| |||||||||||
| COUMA | 10, 50, 150 | 83 (9.3) | 93 (2,9) | 104 (3.8) | 88 (8.3) | 95 (5.8) | 106 (4.7) | 1.0 | 5.0 | 84 (6.0) | 99 (3.6) |
| COUMA-O | 5, 50, 200 | 95 (3.7) | 89 (3.9) | 98 (1.6) | 96 (6.6) | 92 (3.4) | 99 (3.2) | 0.25 | 1.0 | 93 (5.6) | 102 (2.5) |
| HALOX | 20, 80, 200 | 94 (11.7) | 94 (3.6) | 100 (2.0) | 90 (11.8) | 94 (5.3) | 102 (3.1) | 1.0 | 5.0 | 83 (0.8) | 99 (0.6) |
|
| |||||||||||
| MONE | 10, 50, 150 | 103 (5.1) | 96 (4,3) | 93 (3.2) | 104 (12.1) | 97 (6.0) | 94 (5.2) | 0.5 | 5.0 | 90 (6.9) | 96 (3.0) |
| MONE-SO2 | 5, 50, 150 | 94 (8.1) | 91 (6.2) | 93 (3.2) | 98 (8.9) | 94 (4.6) | 98 (5.3) | 0.2 | 1.0 | 92 (2.6) | 102 (1.7) |
|
| |||||||||||
| CLOR | 80, 300, 800 | 95 (12.8) | 97 (5.8) | 95 (4.9) | 96 (14.9) | 95 (10.0) | 94 (8.4) | 10 | 40.0 | 101 (11.6) | 110 (3.6) |
WLr = Within-laboratory repeatability while RSDr = Relative standard deviation under repeatability conditions, WLR= Within-laboratory reproducibility, while RSDwR = Relative standard deviation under reproducibility conditions LOD = Limit of Detection based on S/N = 5, LOQ = Limit of Quantitation based on S/N = 10, L1, L2 and L3, refer to each of the three levels at which the validation was performed.
Preparation of for matrix matched calibration, with corresponding sample concentrations
| Spiking Vol. (µL) | Calibration Level | Concentration Ranges (ng L−1) for Analyte Group a: | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | H | I | J | ||
| 100 | 0.5 × L1 | 20 | 10 | 5 | 0.5 | 1 | 0.5 | 2 | 2 | 2.5 | 2.5 |
| 200 | L1 | 40 | 20 | 10 | 1 | 2 | 1 | 4 | 4 | 5 | 5 |
| 200 | L2 | 80 | 40 | 20 | 5 | 5 | 5 | 6 | 6 | 20 | 10 |
| 200 | L3 | 200 | 100 | 40 | 20 | 20 | 20 | 10 | 10 | 40 | 20 |
| 200 | L4 | 300 | 150 | 80 | 50 | 50 | 50 | 14 | 14 | 80 | 50 |
| 200 | L5 | 400 | 200 | 100 | 100 | 100 | 100 | 18 | 18 | 100 | 100 |
| 200 | L6 | 800 | 500 | 200 | 150 | 200 | 200 | 20 | 20 | 200 | 150 |
| 200 | L7 | 1000 | 1000 | 500 | 200 | 500 | 500 | 22 | 22 | 500 | 200 |
| 400 | L8 (2 × L7) | 2000 | 2000 | 1000 | 400 | 1000 | 1000 | 25 | 25 | 1000 | 400 |
a Analytes within each concentration range group are as described in Section 3.2.
Figure 3Summary of experimental conditions carried out for the response surface model.